AgeX Therapeutics, Inc.
About AgeX Therapeutics, Inc.
The mission of AgeX is to apply technology related to pluripotent stem cells and telomere biology to aging and age-related disease. AgeX is expected to have three initial areas of focus: 1) the development of pluripotent stem cell-derived brown adipocytes for the treatment of Type II diabetes and potentially obesity; 2) the development of vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease; and 3) Induced Tissue Regeneration (iTR)TM - an emerging technology invented and patented by BioTime scientists that is designed to profoundly reprogram aged tissues in the body in a way that can restore a regenerative phenotype normally expressed only in the first few weeks of human development.95 articles about AgeX Therapeutics, Inc.
-
AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
6/5/2018
Bestselling financial writer and visionary joins AgeX Board as Company enters next phase of growth
-
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
5/29/2018
BioTime, Inc., has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”).
-
AgeX Announces NIH Grant Award
5/2/2018
AgeX Therapeutics, Inc. announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH).
-
BioTime Announces Cash Sale of Ascendance Biotechnology
3/27/2018
BioTime subsidiary, AgeX, to receive up to $3.5 million in cash
-
AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018
3/1/2018
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic Investment Conference, March 6-9 in San Diego; Undoing Aging, March 15-17 in Berlin, Germany; and the 10th World Congress and Expo on Cell & Stem Cell Research, March 19-21 in New York City.
-
AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
1/18/2018
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc., today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit (WSCS) on Thursday, January 25, 2018 at the Hyatt Regency Miami.
-
AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
1/2/2018
AgeX today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging.
-
AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference
12/4/2017
This year’s conference will focus on the theme, “The Path Forward for Regenerative Medicine: Traversing the Lab to the Patient.”
-
AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economist’s Conference "The Business of Longevity: Health Innovation for an Ageing World" October 27 in Hong Kong
10/26/2017
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. , announced today that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co- CEO of BioTime, is giving an interview as part of The Economist magazine’s conference.
-
BioTime Board Of Directors Approves Distribution Of AgeX Therapeutics, Inc. Shares To BioTme Shareholders
9/25/2017
-
AgeX Therapeutics, Inc. CEO Michael D. West To Participate In Fireside Chat With J. Craig Venter At The Cell & Gene Therapy CEO Forum
9/21/2017
-
AgeX Therapeutics, Inc. Closes $10 Million Capital Raise
8/17/2017
-
AgeX Therapeutics, Inc. CEO Michael D. West, Ph.D. To Deliver Keynote Address On Biotechnology And Aging At RAAD Festival
8/9/2017
-
BioTime Subsidiary AgeX Therapeutics, Inc. Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery
7/13/2017
-
Bay Area's BioTime Launches New Subsidiary AgeX Therapeutics, Inc. to Develop Its Human Aging Programs
4/6/2017